Women, Blood Pressure & T2D: Closing the Care Gap
- t2diabetesnetwork
- 22 hours ago
- 6 min read
Written by Clare Koning, RN, PhD | April 2026 I 6 min read
Key Highlights
✅ Women with T2D have higher heart disease mortality but are underrepresented in research
✅ GDM signals long-term T2D and CVD risk beyond pregnancy
✅ Perimenopause is a key window as BP risk rises early
✅ Women are often under-prescribed CVD therapies
✅ Sex-specific BP targets and screening improve care
There is a persistent gap in how women with type 2 diabetes (T2D) and hypertension are understood, diagnosed, and treated, and it has real consequences. For decades, landmark studies enrolled predominantly male participants, and clinical guidelines were built on that evidence base. Women were assumed to respond similarly.
They do not.
That assumption is now being corrected, but the pace of change in research has not yet translated into clinical practice. Women with T2D remain at disproportionately elevated cardiovascular risk, and the systems designed to protect them frequently fall short. Understanding why, and what to do about it, is one of the most urgent challenges in cardiometabolic care today.
A Higher Risk, a Lower Priority
The statistics are stark. Women with T2D face a substantially greater relative increase in cardiovascular disease (CVD) risk compared to men with T2D, research suggests women lose more of the cardiovascular protection that typically accompanies female sex than men do when diabetes enters the picture. Put simply: diabetes erases more of women's biological advantage.
Despite this, women remain more likely to have their cardiovascular symptoms attributed to anxiety or non-cardiac causes, to wait longer for diagnosis and intervention, and to receive guideline-directed therapies at lower rates. The result is a care gap that compounds an already elevated biological risk.
Diabetes erases more of women's cardiovascular advantage , yet clinical systems have been slower to respond to female-specific risk than the evidence demands.
Hormonal Life Events: More Than Reproductive Milestones
One of the most clinically important, and historically underappreciated, areas is the role of hormonal transitions in shaping cardiometabolic risk in women. These are not just reproductive events. They are metabolic inflection points.
Gestational Diabetes: The Signal That Persists
Gestational diabetes mellitus (GDM) affects approximately 16% of pregnancies globally and has long been treated as a transient condition, something that resolves after delivery.
It does not.
Women who experience GDM have a significantly elevated lifetime risk of developing T2D, and carry an independent increased risk of hypertension and cardiovascular disease that extends decades beyond the pregnancy. Studies show that women with a history of GDM are nearly twice as likely to develop cardiovascular disease compared to those with normoglycemic pregnancies, even in the absence of a subsequent T2D diagnosis.
Clinical Implication
A GDM diagnosis should trigger ongoing postpartum follow-up: glucose testing at 6–12 weeks post-delivery, annual or biennial metabolic screening, and early cardiovascular risk assessment, not a single post-delivery check and discharge.
Perimenopause: The Window We Have Been Missing
Perimenopause, the years-long hormonal transition before menopause, is emerging as one of the most significant and underutilized windows for cardiovascular prevention in women. Blood pressure begins to rise during this period, driven by declining estrogen, sympathetic nervous system activation, and changes in vascular tone and body composition. This rise frequently predates the onset of recognizable symptoms and can go undetected for years.
For women who already carry T2D or are at cardiometabolic risk, this hormonal-vascular interaction creates a compounding hazard. The traditional model of cardiovascular screening at midlife, waiting for menopause to arrive before assessing BP trajectory, misses the moment of greatest intervention potential.
Menopause and Beyond
The post-menopausal period brings a further shift. Loss of estrogen's vasodilatory and anti-inflammatory effects accelerates arterial stiffening and increases both systolic BP and LDL cholesterol. Women with T2D entering menopause face the convergence of insulin resistance, hypertension, dyslipidemia, and weight redistribution, often simultaneously and often without adequate clinical recognition.
The picture is further complicated by symptom presentation. Women are more likely to present with atypical cardiovascular symptoms, fatigue, jaw or neck pain, nausea, shortness of breath, that are less likely to trigger cardiac investigation than the "classic" chest pain presentation more common in men.
The Under-Prescribing Problem for Women
Vanita Aroda, MD, Associate Professor of Medicine at Harvard Medical School, and Katherine Tuttle, MD, Professor of Medicine at the University of Washington, discuss current disparities in the treatment of women with type 2 diabetes and cardiorenal risk despite the evidence and breadth of available agents. They discuss that women are less likely to receive guideline-directed medical therapy, including both older and newer agents, and less likely to enroll in clinical trials, as well as the need to recognize and address these disparities. Recorded during 2023 CMHC's Women's Health Masterclass, August 19, 2023.
Even when cardiovascular risk is identified in women with T2D, the therapeutic response is often inadequate. Multiple studies and registries have documented that women are less likely to receive guideline-directed pharmacological therapies, including ACE inhibitors, statins, and antiplatelet agents, at rates comparable to men, even when clinical indications are equivalent.
This is not a minor discrepancy. These are medications with demonstrated mortality benefit. Under-prescribing in this population translates directly into preventable cardiovascular events.
Therapy | Evidence in T2D + CVD | Documented Gap in Women |
Statins | Reduces major cardiovascular events by 20–25% | |
ACE inhibitors / ARBs | Renoprotective & cardioprotective in T2D | |
SGLT2 inhibitors | Proven CV and renal benefit in T2D | |
GLP-1 receptor agonists | CV risk reduction & weight benefit |
Systemic Barriers to Equitable Care
The care gap is not only clinical, it is systemic. Women face a cluster of barriers that compound their biological risk. These include greater likelihood of dismissal of cardiovascular symptoms, lower rates of referral to cardiac rehabilitation, financial and caregiving responsibilities that reduce capacity to engage with follow-up care, and implicit bias in clinical assessment that continues to shape referral and prescribing patterns.
Research representation has also been structurally inequitable. For decades, women, particularly women of reproductive age, were routinely excluded from cardiovascular and metabolic trials. The evidence base that informs current guidelines was built largely on male physiology. This is beginning to change, with regulatory agencies and funders increasingly mandating sex-disaggregated data, but the downstream effect on clinical practice will take years to fully materialize.
What Providers Can Do for Women Today
Closing the care gap does not require waiting for new research. There are practical, evidence-supported steps that clinicians can implement now to better serve women with T2D and cardiovascular risk.
Take GDM Seriously as a Long-Term Signal
Implement structured postpartum follow-up protocols for all patients with GDM history: glucose tolerance testing at 6–12 weeks, annual metabolic review, and early CVD risk stratification. Do not let the post-delivery window close without establishing a long-term care pathway.
Begin BP Monitoring at Perimenopause – Not After
For women with T2D, metabolic syndrome, or cardiometabolic risk factors, begin proactive BP monitoring and cardiovascular risk assessment at the first signs of perimenopausal transition, typically the mid-40s. Don't wait for menopause to act on BP trajectory.
Apply Sex-Informed BP Targets
Emerging evidence suggests women may benefit from tighter BP targets than have historically been applied. Until sex-specific guidelines are updated, consider the lower end of recommended BP ranges for women with T2D and additional cardiovascular risk factors.
Audit Prescribing Patterns for Equity
Conduct regular practice audits comparing guideline-directed therapy prescribing rates between male and female patients. Where gaps exist, examine the clinical rationale, and in the absence of contraindications, close them.
Educate Patients on Atypical Symptom Presentation
Women need to know that heart attack and cardiovascular crisis can present differently in them, and that fatigue, nausea, and jaw pain are symptoms that warrant urgent attention, not a low threshold for dismissal. This conversation belongs in routine clinical care, not only in the acute setting.
Research Is Catching Up – Practice Must Follow
The scientific community has recognized the gap and is working to close it. Sex-disaggregated analyses are becoming standard in major cardiovascular trials. Hormonal transitions are being studied as cardiometabolic inflection points rather than reproductive footnotes. Female-specific CVD risk calculators are in development.
But research findings take time to reach clinical practice, and women with T2D are navigating the healthcare system now. The steps outlined above are not aspirational, they are feasible within current clinical frameworks, supported by existing evidence, and overdue.
